Heterozygous ATM mutations do not contribute to early onset of breast cancer

Ataxia telangiectasia (AT) is a recessive syndrome, including cerebellar degeneration, immunologic defects and cancer predisposition^1,2, attributed to mutations in the recently isolated ATM (ataxia telangiectasia, mutated) gene3. AT is diagnosed in 1/40,000 to 1/100,000 live births, with carriers calculated to comprise 1% of the population. Studies of AT families have suggested that female relatives presumed to be carriers have a 5 to 8-fold increased risk for developing breast cancer4,5, raising the possibility that germline ATM mutations may account for 5% of all breast cancer cases. The increased risk for breast cancer reported for AT family members has been most evident among younger women, leading to an age-specific relative risk model predicting that 8% of breast cancer in women under age 40 arises in AT carriers, compared with 2% of cases between 40−59 years6. To test this hypothesis, we undertook a germ-line mutational analysis of the ATM gene in a population of women with early onset of breast cancer, using a protein truncation (PTT) assay to detect chain-terminating mutations, which account for 90% of mutations identified in children with AT7−11. We detected a heterozygous ATM mutation in 2/202 (1%) controls, consistent with the frequency of AT carriers predicted from epidemiologic studies. ATM mutations were present in only 2/401 (0.5%) women with early onset of breast cancer (P = 0.6). We conclude that heterozygous ATM mutations do not confer genetic predisposition to early onset of breast cancer.

1. Shiloh, Y. Ataxia-telangiectasia: closer to unraveling the mystery. Eur. J. Hum. Genet 3, 116−138 (1995). | PubMed  | ISI | ChemPort |
2. Morrell, D. Cromartie, E. & Swift, M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J. Natl. Cancer Inst. 77, 89−92 (1986). | PubMed  | ChemPort |
3. Savitsky, K. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749−1753 (1995). | PubMed  | ISI | ChemPort |
4. Swift, M. Reitnauer, P. Morrell, D. & Chase, C. Breast and other cancers in families with ataxia-telangiectasia. New Engl. J. Med. 316, 1289−1294 (1987). | PubMed  | ISI | ChemPort |
5. Swift, M. Morrell, D. Massey, R. & Chase, C. Incidence of cancer in 161 families affected by ataxia-telangiectasia. New Engl. J. Med. 325, 1831−1836 (1991). | PubMed  | ISI | ChemPort |
6. Easton, D. Cancer risks in A-T heterozygotes. Int. J. Radiat Biol. 66, S177−182 (1994). | PubMed  | ISI | ChemPort |
7. Gilad, S. et al. Predominance of null mutations in ataxia-telangiectasia. Hum. Mol. Genet. 5, 433−439 (1996). | Article | PubMed  | ISI | ChemPort |
8. Byrd, P. et al. Mutations revealed by sequencing the 5' half of the gene for ataxia telangiectasia. Hum. Mol. Genet. 5, 145−149 (1996). | Article | PubMed  | ISI | ChemPort |
9. Telatar, M. et al. Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening. Am. J. Hum. Genet. 59, 40−44 (1996). | PubMed  | ISI | ChemPort |
10. Wright, J. et al. A high frequency of distinct ATM gene mutations in ataxia-telangiectasia. Am. J. Hum. Genet. 59, 839−846 (1996). | PubMed  | ISI | ChemPort |
11. Baumer, A. Bernthaler, U. Wolz, W. Hoehn, H. & Schindler, D. New mutations in the ataxia telangiectasia gene. Hum. Genet. 98, 246−249 (1996). | Article | PubMed  | ISI | ChemPort |
12. Wooster, R. et al. Absence of linkage to the ataxia-telangiectasia locus in familial breast cancer. Hum. Genet. 92, 91−94 (1993). | PubMed  | ISI | ChemPort |
13. Vorechovsky, I. et al. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res. 56, 2726−2732 (1996). | PubMed  | ISI | ChemPort |
14. Vorechovsky, I. et al. ATM mutations in cancer families. Cancer Res. 56, 4130−4133 (1996). | PubMed  | ISI | ChemPort |
15. FitzGerald, M. et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset of breast cancer. New Engl. J. Med. 334, 143−149 (1996). | Article | PubMed  | ISI | ChemPort |
16. Pippard, E.C. Hall, A.J. Barker, D.J.P. & Bridges, B.A. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res. 48, 2929−2932 (1988). | PubMed  | ISI | ChemPort |
17. Borresen, A.L. Anderson, T.I. Treti, S. Heiberg, A. & Muller, P. Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. Genes Chrom. Cancer 2, 339−340 (1990). | PubMed  | ISI | ChemPort |
18. Athma, P. Rappaport, R. & Swift, M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet. Cytogenet. 92, 130−134 (1996). | Article | PubMed  | ISI | ChemPort |
19. Cunliffe, P.N. Mann, J.R. Cameron, A.H. Roberts, K.D. & Ward, H.W.C. Radiosensitivity in ataxia-telangiectasia. Br. J. Radiol. 48, 374−376 (1975). | PubMed  | ISI |
20. Taylor, A.M.R. et al. Ataxia-telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 258, 427−429 (1975). | PubMed  | ISI | ChemPort |
21. Houldsworth, J. & Lavin, M. Effect of ionizing radiation on DNA synthesis in ataxia telangiectasia cells. Nucleic Acid Res. 8, 3709−3720 (1980). | PubMed  | ISI | ChemPort |
22. Cole, J. et al. Comparative human cellular radiosensitivity. II The survival following gamma-irradiation of unstimulated (G°) T lymphocytes, T lymphocyte lines, lymphoblastoid cell lines and fibroblasts from normal donors, from ataxia-telangiectasia patients, and from ataxia-telangiectasia heterozygotes. Int. J. Radiat Biol. 54, 929−943 (1988). | PubMed  | ISI | ChemPort |
23. Beamish, H. & Lavin, M. Radiosensitivity in ataxia-telangiectasia. Anomalies in radiation-induced cell cycle delay. Int. J. Radiat. Biol. 6, 175−184 (1994).
24. Thacker, J. Cellular radiosensitivity in ataxia-telangiectasia. Int. J. Radiat. Biol. 66, 587−596 (1994).
25. West, C. Elyan, S. Berry, P. Cowan, R. & Scott, D. A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients, individuals with ataxia-telangiectasia (A-T) and A-T heterozygotes. Int. J. Radiat. Biol. 68, 197−203 (1995). | PubMed  | ISI | ChemPort |
26. Jorgensen, T.J. & Shiloh, Y. The ATM gene and the radiobiology of ataxia-telangiectasia. Int. J. Radiat. Biol. 69, 57−537 (1996). | Article | PubMed  |
27. Kastan, M. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587−597 (1992). | Article | PubMed  | ISI | ChemPort |
28. Khanna, K. & Lavin, M. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 8, 3307−3312 (1993). | PubMed  | ISI | ChemPort |
29. Xu, Y. & Baltimore, D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev. 10, 2401−2410 (1996). | PubMed  | ISI | ChemPort |
30. Savitsky, K. et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum. Mol. Genet. 4, 2025−2032 (1995). | PubMed  | ISI | ChemPort |
31. Greenwell, P. et al. TEL1, a gene involved in controlling telomere length in S. cerevisiae, is homologous to the human ataxia telangiectasia gene. Cell 82, 823−829 (1995). | PubMed  | ISI | ChemPort |
32. Morrow, D. Tagle, D. Shiloh, Y. Collins, F. & Hieter, P. TEL1, an S. cerevisiae homolog of the human gene mutated in ataxia telangiectasia, is functionally related to the yeast checkpoint gene MEC1. Cell 82, 831−840 (1995). | PubMed  | ISI | ChemPort |
33. Paulovich, A. & Hartwell, L. A checkpoint regulates the rate of progression through S phase in S. cerevisiae in response to DNA damage. Cell 82, 841−847 (1995). | PubMed  | ISI | ChemPort |
34. Hartley, K. et al. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell 82, 849−856 (1995). | PubMed  | ISI | ChemPort |
35. Hari, K. et al. The mei-41 gene of D. melanogaster is a structural and functional homolog of the human ataxia telangiectasia gene. Cell 82, 815−821 (1995). | PubMed  | ISI | ChemPort |
36. Zakian, V. ATM-related genes; what do they tell us about functions of the human gene? Cell 82, 685−687 (1995). | PubMed  | ISI | ChemPort |
37. Barlow, C. et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159−171 (1996). | PubMed  | ISI | ChemPort |
38. Xu, Y. et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10, 2411−2422 (1996). | PubMed  | ISI | ChemPort |
39. Ramsay, J. Birrell, G. & Lavin, M. Breast cancer and radiotherapy in ataxia-telangiectasia heterozygote. Lancet 347, 1627 (1996). | Article | PubMed  | ISI | ChemPort |
40. Stine, G.J. Population genetics, in The new human genetics, (ed. Kevin Kane) 393−396 (Wm. C. Brown, Dubuque, Iowa, 1989).

	Top

	Top